Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with - PowerPoint PPT Presentation

Pressure BioSciences, Inc. (OTCQB: PBIO) Discovery Starts with Sample Preparation™ Investor Presentation Richard T. Schumacher March 2019 President, CEO, and Founder

FORWARD LOOKING STATEMENTS This presentation may contain forward looking statements that reflect management’s current views and opinions as to the status of the Company’s products, technology and other future events and operations. These statements are neither a promise nor guarantee, but involve risks and uncertainties that could cause actual results to differ materially from those anticipated or indicated. Investors are cautioned that any forward looking statements should be considered in light of such risks and uncertainties including, without limitation, those detailed in the Company’s filings with the Securities and Exchange Commission. 02

COMPANY OVERVIEW (OTCQB: PBIO) Three Business Segments - Three Unique Technology Platforms  Research Products and Services ( PCT Platform ) • PCT: Pressure Cycling Technology (alternating cycles of high/low pressure to control biomolecules) • Focus: to streamline and improve the characterization and quality control of protein therapeutics for the Biopharma market. Also offers an effective means of rapid, consistent, and reliable sample preparation for biomarker and target discovery and clinical diagnostics and research laboratories. • 15 Patents, 325 PCT Systems installed, 200+ customers, 120+ publications, 2017 revenue ($2.24M)  Biopharma Contract Services ( Barofold Platform ) • Barofold: Pressure Enabled Disaggregation and Controlled Re-folding of Proteins • Focus: to improve the quality of protein therapeutics, accelerate therapeutic protein development, and manufacture follow-on biologics by employing high pressure for disaggregation & controlled refolding of recombinant proteins into their native structures for desired drug activity. • 8 Patents, Dec 2017 BaroFold Acquisition, Commercial Launch of BCS Business on Jan 7, 2019  Nanoemulsion Manufacturing Services ( UST Platform ) • UST: Ultra Shear Technology (combines high hydrostatic pressure & intense shear forces) • Focus: to produce higher quality, more stable nanoemulsions with improved absorption, higher bioavailability, and lower surfactant levels: food, pharmaceuticals, nutraceuticals, cosmetics, lubricants, paint, and cannabis oil extracts (water soluble CBD) compared to standard emulsions 3

COMPANY MANAGEMENT (OTCQB: PBIO) • Mr. Richard T. Schumacher, President & CEO Boston Biomedica (CEO, Founder); Panacos Pharma (President, Co-founder); Trinity Biotech (Founding Group); CBR Labs (Gen’l Mgr) - Harvard Medical School • Dr. Edmund Y. Ting, Senior VP of Engineering Avure Technologies (CTO); Flow Int’l (VP R&D); Grumman Aerospace; Pioneer in High Pressure Processing for “Clean Label”, Safe Food; MIT (Ph.D.) • Dr. Alexander V. Lazarev, Senior VP and CSO Proteome Systems; Genomic Solutions; ESA; University of Kazan (Ph.D.) • Dr. Bradford A. Young, Senior VP and CCO AddisonField Corp; Nodality; Quest Diagnostics; Celera; Un. Of MD (Ph.D.), UC Berkeley (MBA) • Mr. Richard Thomley, Financial Advisor (former PBI CFO, now retired) Board • Jeffrey Peterson, MS Board Chairman Serial Entrepreneur; Abbott, GE; BSChE/MSCE – MIT • Kevin Pollack, Esq., MBA Chairman: Audit Committee • Vito Mangiardi, MBA Chairman: Compensation Committee • Mickey Urdea, Ph.D. Chairman: SAB • Richard T. Schumacher CEO, Treasurer, Clerk 4

RESEARCH PRODUCTS & SERVICES PCT Platform 02

QUALITY OF ANALYSES IN RESEARCH STUDIES (DISCOVERY TO CLINIC) DEPENDS SIGNIFICANTLY ON THE QUALITY OF SAMPLE PREPARATION 6

Three Critical Functions in Scientific Research Studies Sample Input Quality = Sample Result Quality Data Data Sample Sample Analysis Analysis Reduction & Reduction & Preparation Preparation Interpretation Interpretation  Quality of Analytical Equipment & Data Reduction has Increased Over Recent Years  Quality of Methods for Sample Preparation have not Increased Proportionally (weak link)  Quality of Results is Significantly Affected by the Quality of the Sample Preparation  Scientific Discoveries Start with Sample Preparation 7

VALUE PROPOSITION: RESEARCH & BIOPHARMA INDUSTRY • Analysis of Proteins, Lipids, DNA, RNA, and Small Molecules (“biomolecules”) from Biological Samples is the Backbone of the Research & Biopharma Industry (Discovery to Clinic) • Quality of Results Depends Significantly on Quality of Sample Preparation • Current Sample Preparation Methods are Highly Inadequate: Bottleneck • PCT: Proven Sample Prep Platform with ~ 300 PCT Systems Installed in about 200 Different Sites Worldwide • 120+ Publications Highlight the Advantages of the PCT Platform in Research, Biopharma Sample Preparation (from Discovery to Characterization to QC to Clinic), Protein Therapeutics Characterization and QC • Biological Sample Preparation (Proteomics, Genomics, Lipidomics, Metabolomics) is a Multi-Billion Dollar Market Comprised of an Estimated 500,000 Scientists in 80,000 Research Labs Worldwide 8

VALUE PROPOSITION: BIOPHARMA INDUSTRY GENOMICS NEXT GEN MASS SPECTROMETRY SAMPLE PREP (DNA/RNA) SEQUENCING (DNA) (PROTEINS) FOR ALL OMICS $7.1B in 2015 b $2.7B in 2017 c $2.7B in 2011 a,d $8.4B in 2016 e 500,000 SCIENTISTS ALL BIOPHARMA ALL PROTEOMICS IN 80,000 BIOLOGICAL $160.44B in $21.87B in RESEARCH LABS 2014 f WORLDWIDE a 2021 f a EMMES Group | b Decisive Bio-Insights | c Markets & Markets | d TechNavio | e bcc Research | f Research and Markets 9

BAROCYCLER 2320EXT: EXTREME INSTRUMENT FOR BIOLOGICAL SAMPLE PREPARATION & QC (DISCOVERY TO CLINIC) SPECIFICATIONS - cGxP-compliant data logging and audit trails - 16 samples per batch - Full support for MicroPestle platform - Pressure: up to 45,000 psi (3.1 kilobar) - Temperature: 4 ° C to 95 ° C (external chiller) or Ambient to 95 ° C (built-in electrical heater) - Unlimited pressure programming - Real-time graphs of pressure and temperature - Enhanced security and user management - Safe low voltage (24V DC) operation 10

PBI INSTRUMENT PORTFOLIO BAROCYCLER™ HUB440 - HUB880 BAROZYME HT48 XSTREAMPCT™ 2320EXT Up to 45,000 psi. Award- Up to 58,000 & Up to 20,000 psi. Up to 58,000 winning, next-generation, 100,000 psi. High throughput psi. On-line multi-functional sample All-purpose pressure analyses sample preparation instrument generators processors 4 1 2 3 5 6 7 Up to 25,000 psi. Lab-Scale UST Novel Pressure Homogenizers Pump EXPLORER ULTRA-SHEAR RF 1700 11 DISCOVERY PLATFORM TECHNOLOGY (UST)

APPLICATIONS OF PBI PRODUCTS & SERVICES SPAN ACROSS ALL BIOPHARMA MARKET SEGMENTS FROM DISCOVERY TO CLINIC DEVELOPMENT DISCOVERY CLINIC 12

PCT PLATFORM IN THE LABS OF KOLS WORLDWIDE Professor J. Van Eyk Prof. Patricia Okubara Professor Cathy Royer Professor Wayne Hubbell Cedars Sinai USDA – WSU Rensselaer Poly. Inst. UCLA Biomarker Discovery Biomarker Discovery Protein Folding Kinetics Protein Structure Heart Disease Microbe Diversity in Soil Rational Drug Design Drug Discovery & Design Professor Bruce Kristal Professor Bruce McCord Prof. Ruedi Aebersold Prof. Phil Robinson Harvard Medical School Florida Int’l Univ. ETH, Zurich, Switzerland ProCan (CMRI), Sydney, AU Metabolomics/Lipidomics Forensics – DNA Testing WW Proteomic Leader Proteomic Mass Spec for Fecal Lipidomic Profiling Improved Rape Kit Testing Tissue Biopsy Analysis by PCT-SWATH Precision Medicine & Therapy 13

BIOPHARMA CONTRACT SERVICES BAROFOLD Platform 02

BaroFold Asset Acquisition: 12/13/17 BAROFOLD Technology Platform Patented Process for Disaggregation and Controlled Refolding of Proteins 8 Issued Patents: Extends Some Current Coverage & Adds New Coverage • Almost All New Drugs are Biological not Chemical • Over 200 Protein Drugs on Market – Many Additional Protein Drugs in Development • Proteins - as Large Protein Molecules - Can Aggregate and Misfold in Manufacturing • Pressure (Barofold Platform) Can Disaggregate and Refold Proteins • Improves Quality of Protein Drugs and Reduces Cost of Manufacturing • Barofold Technology Platform Works Well on PBI Instruments (R&D) • BaroFold Investors Requested Majority of Purchase Price in PBIO Stock • Potential to Generate Millions of Dollars in Annual Royalty Revenue from Biopharmaceutical Company Licenses 15

BAROFOLD PATENTS FOR PROTEIN DISAGGREGATION AND CONTROLLED REFOLDING (Pre-EMT) SPAN ACROSS SAME BIOPHARMA COMPANIES AS PBIO’S CORE PCT BUSINESS DEVELOPMENT DISCOVERY CLINIC 16

NANOEMULSION MANUFACTURING EQUIPMENT, LICENSING & SERVICES UST PLATFORM 17

USDA Project Goal As announced on Tuesday, July 10, 2018 USDA funded project ($891K) with Ohio State Univ. and Pressure BioSciences ($318K) Validate and demonstrate commercial (pilot) scale production of high value, high quality dairy products using PBI’s patented Ultra Shear Technology (UST) 18 02